FDA peptide vote 2026: HHS stopgap filed, no rule yet

Six of seven peptides were recommended. None of them became legal. On 23 and 24 July 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for the 503A Bulks List and voted down emideltide (DSIP). Every vote was narrow, and FDA's own review scientists had recommended against all seven. As of 10 October 2026 no US pharmacy can lawfully compound any of the six, and FDA has published no proposed rule.

The vote does nothing for research peptides sold online. Compounding pharmacies and research-chemical vendors sit under different parts of federal law, so a vial bought online is as legal, and as unverified, as it was on 22 July.

What did the Washington Post report about a peptide stopgap?

On 7 October 2026 the Washington Post reported that the administration is "crafting plans" to allow the temporary sale of certain previously restricted peptides through compounding pharmacies while regulators write permanent rules. Its sources were two people speaking on condition of anonymity. The original is paywalled; we read the full text through the dnyuz syndicated copy of 8 October.

The Alliance for Pharmacy Compounding (APC) confirmed its own part. Its CEO told the Post the group met FDA twice to ask for interim enforcement discretion, conditioned on patient disclosures, serious adverse-event reporting and data collection. APC's 9 October post says the report "simply affirms rumors" it had been hearing. That confirms the lobbying, not the plan. The Post also cites a polling memo commissioned by the American Academy of Peptide Medicine that describes a "political upside" to wider access; we have not seen the memo.

Did FDA staff object?

According to Pink Sheet, yes. Its 8 October report, "US FDA Staff Push Back Against Trump Administration Interim Peptide Dispensing Order", carries the summary line that FDA drug-center staff "will not recommend allowing temporary compounding of unapproved peptides." The article is paywalled and we have read only the headline and summary.

A day later, in a third-party summary of Pink Sheet's Drug Fix podcast, a Pink Sheet reporter says HHS is preparing to finalize a temporary order over the objections of CDER staff, who cite missing clinical testing and the risk to the drug-approval system. The same summary says the announcement could come from HHS or the White House Domestic Policy Council. We have not heard the full audio, so treat "finalize" as Pink Sheet's reporting relayed by a summariser. The staff position matches July, when FDA's reviewers recommended against all seven peptides.

What is official so far?

Nothing. We checked on 10 October 2026:

Our reading, not something the Post reported: a temporary order would most likely work as enforcement discretion, which FDA can announce by guidance or statement without notice-and-comment rulemaking. That makes it faster than a rule and easier to reverse.

Has FDA acted on the July vote yet?

No. Eleven weeks after the meeting, FDA has published no proposed rule, no Federal Register notice and no interim Category 1 decision for any of the six. The July meeting page lists briefing documents, the roster and FDA's slides, but no minutes and no vote results (checked 10 October). A thread on r/tirzepatidecompound asked: "So this hasn't just quietly happened, right?" (thread). It has not.

Which peptides are next for the PCAC?

FDA's meeting page says the committee will meet "before the end of February 2027" on five more bulk substances nominated for the 503A list. As of 10 October 2026 FDA had set no date and published no Federal Register notice or docket. All five came off Category 2 in April but were not on the July agenda. A vote in early 2027 would leave them where BPC-157 is today: recommended, not legal.

What did the FDA peptide committee actually vote on?

Seven bulk drug substances nominated for the 503A Bulks List, the register of ingredients a traditional compounding pharmacy may use when preparing an individual prescription.

Tallies are from McDermott Will and Emery's meeting summary. FDA has posted no official tally, and other summaries differ: Frier Levitt, as reported by Dispense Times, gives Epitalon 7-5 and DSIP rejected 7-6. We have not confirmed any margin against an FDA record. In every published version the margin was three votes or fewer, and one seat on BPC-157, KPV or TB-500 would have made it 7-7.

Did FDA's own scientists support this?

No. Agency review staff recommended against all seven nominations, citing insufficient safety data, insufficient efficacy data and incomplete characterization of the substances.

On BPC-157, reviewers pointed to a lack of evidence for effectiveness in the nominated indication and wrote that the peptide is not well characterized, so the agency cannot set quality standards for it. That is a manufacturing-controls objection: FDA says it does not know enough about what BPC-157 is to write a specification. The committee voted the other way. Advisory committees need not follow staff review, and FDA need not follow advisory committees.

Is BPC-157 legal now?

No. As of 10 October 2026 a US pharmacy cannot lawfully compound BPC-157, and FDA has approved no BPC-157 drug. FDA's warning letters to research-peptide sellers treat products marketed for human use as unapproved new drugs, whatever the "research use only" label says.

Online sellers remain exposed to FDA warning letters and, on the GLP-1 side, to Eli Lilly's lawsuits. Our BPC-157 guide holds the testing data.

The formal route has four stages, and two are done.

  APRIL 2026            JULY 2026              NOT YET                 NOT YET
  ┌──────────────┐      ┌──────────────┐      ┌──────────────┐      ┌──────────────┐
  │ Removed from │ ───→ │ PCAC votes   │ ───→ │ FDA proposed │ ───→ │ Final rule.  │
  │ Category 2   │      │ to recommend │      │ rule + public│      │ Substance is │
  │ (12 peptides)│      │ (6 of 7)     │      │ comment      │      │ compoundable │
  └──────────────┘      └──────────────┘      └──────────────┘      └──────────────┘
        DONE                  DONE          not published (10 Oct)      2027+

On 15 April 2026 FDA announced it would remove twelve substances from the Category 2 do-not-compound list, and the committee voted in July. The proposed rule and the final rule are the stages that matter legally, and both are outstanding.

Coming off Category 2 sounds like permission and is not. Removal does not make a substance eligible for compounding under section 503A, and FDA's interim enforcement-discretion policy covers only Category 1 substances. All six recommended peptides sit in that gap: off the do-not-compound list, not on the bulks list, not in Category 1.

FDA can close the gap in two ways. Notice-and-comment rulemaking would formally add the peptides to the 503A Bulks List; legal analysts expect that to reach 2027 at the earliest, possibly over several years. Interim Category 1 status, or a temporary order of the kind the Post describes, would let pharmacies compound under enforcement discretion while rulemaking continues. As of 10 October 2026 the agency has not said which it will do.

Which twelve peptides came off the do-not-compound list?

Five of the twelve substances FDA removed from Category 2 in April were never on the July agenda.

Those five are off the do-not-compound list, have no advisory recommendation behind them and are not on the bulks list. Anyone claiming GHK-Cu or melanotan II got cleared in July is wrong twice over.

Does the vote change anything for research peptides bought online?

No. Section 503A governs what a licensed pharmacy may prepare against a prescription for an identified patient. Peptides sold online as research-grade reagents are not compounded drugs. They fall under FDA's unapproved-drug and misbranding authorities, which neither the vote nor the reported stopgap touches. The two markets share demand, as our 503A and PCAC explainer covers, but they are legally separate, and enforcement against online vendors has been accelerating, not easing.

Expect vendor pages and affiliate posts to describe BPC-157 as FDA-backed, FDA-cleared or newly approved. All three would be false.

The vote says nothing about quality either. Underdosed vials, the wrong compound and certificates that resolve to no lab record are covered in our vendor failure taxonomy. The defence is the same as before July: check the certificate against the issuing lab's own record, which our COA verifier does.

What happens if the six do become compoundable?

They would move from a gray market into a regulated one. A patient with a prescription could get BPC-157 from a 503A pharmacy working under state board oversight, USP standards and pharmacist accountability. For anyone buying online because there was no lawful route, that would be the better product.

It would move the trust question, not answer it. On the compounded GLP-1 side we already see a wide gap between the best and worst 503A operators, so "which pharmacy" would replace "which vendor". For at least the rest of 2026, and plausibly well into 2027, the legal status of all six stays as it is.

Bottom line

An advisory committee narrowly recommended six peptides for a list they are not yet on, against the advice of FDA's reviewers, with a proposed rule and a final rule still to come. A stopgap has been reported, not issued. Treat any claim that BPC-157, TB-500, MOTS-c, Semax, Epitalon or KPV became legal, approved or cleared as a signal about the person making it.

Our guides to BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon carry the research status, regulatory position and third-party purity data for each compound. Start with KPV, the cleanest compound in our certificate corpus, and BPC-157, the most tested, which also holds the single worst result. We will update this page when FDA or HHS issues anything on paper.

Sources

• FDA, Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026 - primary meeting record
• McDermott Will and Emery, PCAC meeting summary - vote tallies and procedural next steps
• Frier Levitt, Category 2 removal analysis - the twelve substances and what removal does not do
• Regulatory Focus (RAPS), advisory committee coverage - FDA staff review positions
• Science, FDA committee votes to make peptides more widely available - 24 July 2026
• FDA, upcoming PCAC meeting (before end of February 2027) - LL-37, GHK-Cu, dihexa acetate, melanotan II, PEG-MGF; read 10 October 2026
• Washington Post, temporary-sale plan, 7 October 2026 - two anonymous sources; paywalled, read via the dnyuz syndicated copy
• Pink Sheet, FDA staff push back, 8 October 2026 - paywalled; headline and summary line only (secondary)
• Pink Sheet Drug Fix podcast, 9 October 2026, via BigGo summary - "finalize a temporary order" claim (third-party summary, secondary)
• Alliance for Pharmacy Compounding, "Peptide plan reportedly in the works" - 9 October 2026
• Federal Register API - FDA documents since 1 October 2026, queried 10 October 2026; FDA press announcements and HHS press room, read 10 October 2026
• Dispense Times, Frier Levitt on the PCAC outcome - alternate tallies and the 12-24 month estimate (secondary)
• Alliance for Pharmacy Compounding letter to FDA - 25 August 2026
• Internal: 503A and the PCAC, FDA peptide enforcement 2024-2026, Lilly's peptide lawsuits, how peptide vendors fail